Desmoteplase 3 to 9 Hours After Major Artery Occlusion Stroke | Zendy

Rüdiger von Kummer | Zendy; Etsuro Mori | Zendy; Thomas Truelsen | Zendy; Jens-Kristian S. Jensen | Zendy; Bjørn Grønning | Zendy; Jochen B. Fiebach | Zendy; KarlOlof Lövblad | Zendy; Salvador Pedraza | Zendy; Javier M. Romero | Zendy; Hugues Chabriat | Zendy; Ku-Chou Chang | Zendy; Antoni Dávalos | Zendy; Gary A. Ford | Zendy; James C. Grotta | Zendy; Markku Kaste | Zendy; Lee H. Schwamm | Zendy; Ashfaq Shuaib | Zendy; Gregory W. Albers | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Desmoteplase 3 to 9 Hours After Major Artery Occlusion Stroke

Author(s) -

Rüdiger von Kummer,

Etsuro Mori,

Thomas Truelsen,

Jens-Kristian S. Jensen,

Bjørn Grønning,

Jochen B. Fiebach,

KarlOlof Lövblad,

Salvador Pedraza,

Javier M. Romero,

Hugues Chabriat,

Ku-Chou Chang,

Antoni Dávalos,

Gary A. Ford,

James C. Grotta,

Markku Kaste,

Lee H. Schwamm,

Ashfaq Shuaib,

Gregory W. Albers

Publication year - 2016

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.116.013715

Subject(s) - medicine , modified rankin scale , odds ratio , stroke (engine) , placebo , confidence interval , adverse effect , randomized controlled trial , anesthesia , surgery , ischemic stroke , ischemia , mechanical engineering , alternative medicine , pathology , engineering

The DIAS-3 trial (Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke [phase 3]) did not demonstrate a significant clinical benefit of desmoteplase administered 3 to 9 hours after stroke in patients with major artery occlusion. We present the results of the prematurely terminated DIAS-4 trial together with a post hoc pooled analysis of the concomitant DIAS-3, DIAS-4, and DIAS-J (Japan) trials to better understand the potential risks and benefits of intravenous desmoteplase for the treatment of ischemic stroke in an extended time window.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research